Aktieanalys

Biovica: Signs its fourth tier-1 oncology Master Service Agreement based on DiviTum - Redeye

{newsItem.title}

Redeye Publicerad: 19 May 10:04

The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 2025 to 2028, suggesting that DiviTum will be used in a more extensive clinical study.

Länk till analysen i sin helhet: https://www.redeye.se/research/1110116/biovica-signs-its-fourth-tier-1-oncology-master-service-agreement-based-on-divitum?utm_source=finwire&utm_medium=RSS

Nyheter om Biovica

Läses av andra just nu

Om aktien Biovica

Senaste nytt